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ABSTRACT 
Bipolar and psychotic disorders are relatively common and likely to have a significant 
impact on quality of life and functioning which, in the context of elite sport, includes a 
potential negative impact on sporting performance. For this narrative review article, 
the literature on bipolar and psychotic disorders in elite athletes was 
comprehensively searched, and little relevant empirical research was found.  A 
diagnosis of bipolar or psychotic disorders may be challenging in elite athletes 
because of complicating factors related to the modifying role of exercise and 
potential precipitating impact of substance use.  Medications used to treat bipolar 
and psychotic disorders may have side effects particularly problematic for elite 
athletes. Future research should be tailored to the specific characteristics and needs 
of elite athletes and to the sporting context in which the disorders may arise. 
Specifically, further research is needed on the prevalence and incidence of these 
conditions in elite athletes and the impact of both the disorders and their treatments 
on sporting performance. 
 
Keywords – psychiatry, disorder, sport, athlete, elite performance  
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INTRODUCTION 
The typical age of onset of bipolar and psychotic disorders coincides with average 
peak performance in elite athletes [1], yet information on their prevalence in elite 
athletes and their impact on athletic performance is limited. Furthermore, evidence to 
guide the clinician who is providing treatment for these conditions in elite athletes is 
primarily based on ‘expert opinion’ and extrapolation from general (non-sporting) 
guidelines. 
 
The purposes of this narrative review are to: a) synthesise the literature on the 
diagnosis, prevalence, impact on performance, and management of bipolar and 
psychotic disorders in elite athletes; and b) provide recommendations based on what 
is currently known. One of the authors (MH) searched key databases (PubMed, 
SportDiscus, PsycINFO, Scopus, and Cochrane) and repeated the searches in 
November 2018 (3 months before intended submission). Figure 1 illustrates the 
search strategy. Search terms relating to the disorders, sports participation, and the 
elite nature of participation were combined. We identified 420 potential references 
and included original studies that: a) were written in English; b) were conducted 
exclusively among current elite athletes; and c) presented information on bipolar or 
psychotic disorders. Twelve references were retained based on these inclusion 
criteria. These were then used by the other authors to identify related references. 
Other literature was also reviewed, where there were gaps in athlete-specific 
literature, for guidance on diagnosis, prevalence, functional impairment, and 
management. Elite athletes were defined as those competing at professional, 
Olympic, or collegiate/university levels. 
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Figure 1. Search strategy 
  
 
 
6 
DIAGNOSIS OF BIPOLAR DISORDER 
Bipolar disorder is a recurrent and often chronic mental health disorder. It is 
characterised by episodes of elevated mood (‘mania’, or when less severe, 
‘hypomania’) and also commonly of depressed mood, with associated change in 
functioning [2].   
 
Mania is characterised by an abnormally and persistently elevated, expansive, or 
irritable mood and disinhibited behaviour [2]. Increased energy and reduced need for 
sleep are typical, and insight is frequently diminished. Psychotic symptoms such as 
delusions or hallucinations can occur, and if present, are usually consistent with the 
individual’s elevated mood (‘mood congruent’). Symptoms of mania must be present 
for at least 7 days and associated with significantly impaired function to permit 
diagnosis of a manic episode.  Lesser degrees of functional impairment, or simply a 
change in functioning without impairment, for at least 4 days are consistent with a 
diagnosis of a hypomanic episode [2]. Episodes of mania and hypomania tend to be 
less frequent, and shorter, than depressive episodes [3,4]. 
 
Episodes of depression are characterised by some or all of the following:  low mood; 
loss of interest or pleasure; reduced energy; changes in sleep and appetite; feelings 
of guilt or worthlessness; thoughts of death or suicide; psychomotor agitation or 
retardation; and poor concentration [2]. Symptoms can last for weeks or more. For 
diagnostic purposes, a minimum of 5 symptoms and duration of 2 weeks is specified 
for a major depressive episode. If psychotic symptoms are present, they are usually 
congruent with the individual’s depressed mood. 
 
Features of both hypomania or mania and depression can be concurrent (described 
as having ‘mixed features’) [2].  For example, an individual may exhibit increased 
activation and social disinhibition, but be dysphoric in mood. This combination may 
appear counterintuitive, but it is more common than often recognised [5]. Individuals 
in such states are at particularly high risk for suicide [6]. 
 
Two main specific subtypes of bipolar disorder are recognised [2]. In bipolar I 
disorder, there has been at least one manic episode (with or without episodes of 
 
 
7 
major depression); in bipolar II disorder, hypomanic and major depressive episodes 
have occurred, with no periods of mania.   
 
Patients with bipolar disorder (especially bipolar II disorder) may be misclassified as 
having a purely depressive illness [7]. Those with shorter hypomanic episodes and 
less functional impairment may not present for medical attention, and if no inquiry is 
made during assessment of a later depressive episode, the diagnosis may be 
missed.  
 
DIAGNOSIS OF PSYCHOTIC DISORDERS 
Psychotic disorders are characterised by symptoms such as hallucinations or 
delusions. In schizophrenia, additional symptoms are required to make the 
diagnosis, including some or all of the following:  disorganised speech; grossly 
disorganised or catatonic behaviours; negative symptoms such as lack of motivation; 
and associated features such as inappropriate affect, cognitive deficits, and 
problems with social cognition. The diagnosis is only made if some symptoms have 
persisted for at least 6 months and significant functional impairment exists [2].   
 
Other psychotic disorders are described and classified [2] and their features are 
summarised in Table 1.  In delusional disorder, there is a narrower range of 
symptoms (primarily delusions).  In brief psychotic disorder, the duration is shorter 
than in schizophrenia.  In schizophreniform disorder, the duration is shorter and 
there is less functional impairment (often a provisional diagnosis).  In schizoaffective 
disorder, mood symptoms occur alongside, and sometimes separate from, psychotic 
symptoms and may be primarily depressive or manic. Attenuated psychosis 
syndrome is not an official Diagnostic and Statistical Manual of Mental Illness (DSM) 
diagnosis but is noted within the DSM as a Condition for Further Study [2], with 
manifestations that reportedly include delusions, hallucinations, or disorganised 
speech in attenuated (or sub-threshold) form but still sufficient to be distressing or 
disabling.  A proportion of individuals with attenuated psychosis syndrome will 
progress to a full psychotic syndrome [8], even when symptoms appear to have 
resolved [9]. Individuals with attenuated psychosis syndrome are at risk for 
developing many non-psychotic disorders that may need treatment, particularly given 
their associations with suicidality [10,11].  
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Table 1. Schizophrenia and psychotic disorders  
Schizophrenia  At least 2 of the following 5 features (at least 1 of which must be 1 of the first 
3):  delusions; hallucinations; disorganised speech; marked behavioural 
disturbance; negative symptoms such as diminished emotional expression or 
avolition 
Marked deterioration in functioning  
Continuous signs of the disturbance for at least 6 moths 
Associated features may support the diagnosis: 
inappropriate affect such as laughing in the absence of an appropriate stimulus 
dysphoric mood with anxiety, anger, or depression 
cognitive deficits (which are strongly linked to functional impairments), e.g., in 
memory, language, and executive functions 
deficits in social cognition, e.g., inability to infer the intentions of others 
Delusional Disorder 1 or more delusions for at least 1 month 
Hallucinations are not prominent and if present relate to the delusional theme (e.g., 
sensations of insect infestation when delusions are of infestation) 
Apart from the impact of the delusion(s) or its ramifications, functioning and behaviour 
are not markedly impaired or bizarre 
Brief Psychotic 
Disorder 
Symptoms of at least 1 of the following:  delusions; hallucinations; disorganised 
speech; disorganised behaviour may or may not be present 
Duration between 1 day and 1 month 
Level of impairment may be severe but eventual return to full functioning 
May occur in response to a severe stressor (and then sometimes called brief 
reactive psychosis) 
Schizophreniform 
Disorder 
Characteristic symptoms identical to schizophrenia (at least 2 of 5 features, at 
least 1 of which must be 1 of the first 3) 
Shorter duration (1 to 6 months) 
May be a provisional diagnosis, i.e., when the patient still has ongoing 
symptoms but it has not yet been 6 months 
Schizoaffective 
Disorder 
An uninterrupted period of the illness during which there is a major mood 
episode (major depressive or manic) concurrent with at least 2 of the 5 features of 
schizophrenia  
Delusions or hallucinations for 2 or more weeks in the absence of a major mood 
episode during the lifetime of the illness 
Symptoms meeting criteria for a major mood episode are present for the 
majority of the total duration of the active and residual portions of the illness  
Classified as bipolar type if any manic episodes have occurred and depressive 
type if mood episodes have been exclusively depressive 
Psychotic Disorder 
Due to Another 
Medical Condition 
Prominent delusions or hallucinations with significant distress or functional 
impairment 
Evidence via history, examination, or laboratory findings that symptoms are the 
direct pathophysiological consequence of the medical condition 
Symptoms not better explained by another mental disorder or by delirium 
Substance/Medicat
ion-Induced 
Psychotic Disorder 
Delusions and/or hallucinations with significant distress or functional impairment 
Symptoms emerge during or soon after substance intoxication or withdrawal 
(per evidence from history, examination, or laboratory findings) 
The substance is known to be capable of producing delusions and/or 
hallucinations 
Symptoms not better explained by another psychotic disorder or by delirium 
Attenuated 
Psychosis 
Syndrome 
Must have 1 of the following at least once per week for the past month :  
delusions; hallucinations; disorganised speech 
Symptoms are distressing and disabling 
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(included in the 
DSM-5 as a 
Condition for 
Further Study) 
Symptoms are below threshold for diagnosis of any other psychotic disorder 
(e.g., less severe and/or more transient) 
 
[2] 
 
Secondary bipolar and psychotic disorders 
Substance/medication-induced bipolar disorder and bipolar disorder due to another 
medical condition are secondary bipolar disorders [2]. Similarly psychotic symptoms 
may also be substance/medication-induced or due to another medical condition [2]. 
Within the general population, some of these secondary disorders are more 
commonly a consideration when there is a later-age presentation [12] as they may 
be associated with conditions such as thyroid disease, multiple sclerosis, and right-
sided cortical or subcortical brain lesions, which are commoner in older populations 
[13]. Of more relevance in sporting populations are traumatic brain injuries, where 
secondary bipolar disorder is a possible although uncommon sequela [14], and 
stimulant or anabolic androgenic steroid (AAS) use contributing to depressive or 
hypomanic symptoms, an unstable mood or psychotic symptoms [15–17].  
 
Sports-specific diagnostic issues 
A diagnosis of bipolar disorder or a psychotic disorder may be more difficult to make 
in an elite athlete. Exercise may be an outlet for the excess energy seen in mania or 
hypomania, which could delay diagnosis. In addition, over-activity may be obscured 
or normalised in the context of athletic training [18].  AAS may be misused by 
athletes for performance reasons [16,19]; the mood disturbance and psychotic 
symptoms that have been reported in association with their use can confuse 
diagnosis. Importantly, though, hypomanic symptoms secondary to AAS are usually 
sub-syndromal and typically only seen when high doses of multiple agents are used 
(often called ‘stacking’) [17,20]. Depressive symptoms have been described among 
athletes withdrawing from AAS use [17,20]. Again, there is an association between 
high dosages and ‘stacking’ and depression [20,21]. However, many studies of this 
topic had small sample sizes, no control groups, multiple potential confounders, and 
cross-sectional designs. Other substances used by some athletes – including 
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stimulants, cannabis, and glucocorticoids – may be associated with psychotic 
symptoms [16,19]. It is important to distinguish primary mood and psychotic 
disorders from substance-induced forms, as the latter may be self-limiting or require 
only short-term treatment [21]. A comprehensive history – supplemented by 
appropriate urine testing and toxicology – is necessary to confirm the diagnosis [22]. 
Table 2 provides a list of features that may help distinguish between primary bipolar 
and psychotic disorders and those secondary to substance misuse by elite athletes. 
 
Table 2. Features that may help distinguish between primary bipolar and psychotic 
disorders and those secondary to substance misuse in sport. 
 Primary disorder Secondary to substance use 
History Possible past history of 
episodes  
Family history of disorder  
No report of substance use 
Use may be acknowledged 
with sensitive enquiry and 
corroborative reports (e.g., 
from family, friends, etc.). 
Clinical features • Symptoms may be similar. 
• Longitudinal course is more 
likely to be of episodes 
lasting weeks or more. 
• Symptoms may be similar. 
• Episodes may self-limit after 
a few days. 
• Irritability and aggression are 
more common. 
• Sub-syndromal presentations 
are more likely than full 
syndromes. 
• Close temporal relationship 
to use 
• Association with high-dose 
and multiple substance use 
Physical exam Signs of increased arousal may 
be present (e.g., increased 
pulse and/or blood pressure). 
The following signs may be 
present: 
• AAS use – acne, needle 
marks, female hirsutism, 
jaundice, gynaecomastia 
(males), breast atrophy 
(females), testicular atrophy 
or prostatic hypertrophy 
(males), clitiromegaly 
(females) 
• Stimulant use – increased 
arousal, dilated pupils, tics  
• Cannabinoid use – 
characteristic smell, 
conjunctival injection, 
drowsy, slowed responses, 
impaired short-term memory 
 
[17,19–22] 
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ASSESSMENT 
For an elite athlete who may have bipolar disorder, the standard assessment begins 
with a detailed history of mood episodes, triggers, and symptoms between episodes, 
with corroboration from a family member or other close informants if possible [23]. A 
detailed history includes all medications (and any supplements or ergogenic aids) 
and will help to diagnose common comorbidities such as anxiety disorders and other 
conditions that may confound the diagnosis. These include personality disorders, 
attention-deficit/ hyperactivity disorder (ADHD), illicit or prescribed drug use or use 
disorders, and medical conditions associated with secondary mania or secondary 
psychosis [13,23,24]. 
 
The role of exercise in an athlete’s symptoms needs to be considered when 
assessing for bipolar disorder. Less frequent exercise is often associated with 
depression, and more frequent exercise with mania [25]; the amount of exercise may 
be a manifestation of the disorder.  
 
Bipolar disorder is unusual compared to other mental health disorders in that regular 
exercise does not seem to offer a protective effect. In a large prospective community 
survey, the incidence of bipolar disorder over a 4-year period was greater in those 
with regular physical activity at baseline [26]. Furthermore, although some bipolar 
patients report that exercise is helpful in mood regulation, directing energy and 
bringing structure to activities, others report that it contributes to spiralling of 
hypomanic and manic symptoms [27]. The type of sport and the nature of the 
physical activity may be relevant. Rhythmic sporting activities (e.g., running, walking, 
and swimming) may be calming and facilitate mood regulation [27]. Conversely, 
participants in extreme or high-risk sports (e.g., mountain biking or rock climbing) 
report high scores on measures of bipolar symptoms [28]. 
 
When considering the role of exercise in the development of hypomanic and manic 
symptoms, some possible mechanisms have been described. Exercise and 
antidepressant medication may share similar biological mechanisms [29] and thus 
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may induce hypomania and mania in patients with bipolar disorder [30]. In addition 
neurobiological systems involved in goal striving and reward seeking (principally 
dopaminergic projections) may be dysregulated in those with bipolar disorder [31]. 
This may explain underlying biological vulnerability as well as the course of the 
disorder via triggers which dysregulate these systems [32]. Of relevance in 
performance sport is that when there is an underlying vulnerability then sporting 
activity via goal striving, reward seeking and goal attainment could act as a trigger 
for manic or hypomanic symptoms [32].  
 
In the assessment process, it therefore may be necessary to consider whether 
sporting activity is a manifestation of the underlying disorder, a helpful way of 
managing symptoms, or a contributory factor to mood instability and especially to 
hypomania and mania.  
 
Psychotic symptoms are experienced by 5-8% of the general population [33] and 
7.5% of 13-18 year olds [10]. Since these symptoms do not necessarily predict overt 
psychotic disorders, careful assessment is warranted. The self-administered 16-item 
Prodromal Questionnaire (PQ16) [34] may be a useful screening tool for psychotic 
disorders (Table 3). The respondent indicates for each item whether this experience 
is ‘True or False’ and indicates how much distress is associated with each ‘True’ 
item, on a Likert scale of 0-3. A score is determined by summing the number of items 
endorsed as ‘True’. A score of 6 or more has optimal sensitivity (87%) and specificity 
(87%) [34] and indicates the respondent may be at risk for psychosis. Athletes who 
meet this cut-off, or who otherwise disclose concerns about psychotic-like 
symptoms, should be referred to specialist mental health services for a more detailed 
clinical history [35]. There are no sports-specific psychosis screening tools. 
 
Table 3. The 16-item version of the Prodromal Questionnaire (PQ-16) by permission 
of the Oxford University Press. 
 
  If TRUE: how much distress did you 
experience? 
  None      Mild    Moderate  Severe 
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1. I feel uninterested in the things I used to 
enjoy. 
☐ True    ☐ False  ☐ 1        ☐ 2        ☐ 3          
☐ 4 
2. I often seem to live through events exactly 
as they happened before (déjà vu). 
☐ True    ☐ False ☐ 1        ☐ 2        ☐ 3          
☐ 4 
3. I sometimes smell or taste things that 
other people can’t smell or taste. 
☐ True    ☐ False ☐ 1        ☐ 2        ☐ 3          
☐ 4 
4. I often hear unusual sounds like banging, 
clicking, hissing, clapping or ringing in my 
ears. 
☐ True    ☐ False ☐ 1        ☐ 2        ☐ 3          
☐ 4 
5. I have been confused at times whether 
something I experienced was real or 
imaginary. 
☐ True    ☐ False ☐ 1        ☐ 2        ☐ 3          
☐ 4 
6. When I look at a person, or look at myself 
in a mirror, I have seen the face change right 
before my eyes. 
☐ True    ☐ False ☐ 1        ☐ 2        ☐ 3          
☐ 4 
7. I get extremely anxious when meeting 
people for the first time. 
☐ True    ☐ False ☐ 1        ☐ 2        ☐ 3          
☐ 4 
8. I have seen things that other people 
apparently can’t see. 
☐ True    ☐ False ☐ 1        ☐ 2        ☐ 3          
☐ 4 
9. My thoughts are sometimes so strong that 
I can almost hear them. 
☐ True    ☐ False ☐ 1        ☐ 2        ☐ 3          
☐ 4 
10. I sometimes see special meanings in 
advertisements, shop windows, or in the way 
things are arranged around me. 
☐ True    ☐ False ☐ 1        ☐ 2        ☐ 3          
☐ 4 
11. Sometimes I have felt that I’m not in 
control of my own ideas or thoughts. 
☐ True    ☐ False ☐ 1        ☐ 2        ☐ 3          
☐ 4 
12. Sometimes I feel suddenly distracted by 
distant sounds that I am not normally aware 
of. 
☐ True    ☐ False ☐ 1        ☐ 2        ☐ 3          
☐ 4 
13. I have heard things other people can’t 
hear like voices of people whispering or 
talking. 
☐ True    ☐ False ☐ 1        ☐ 2        ☐ 3          
☐ 4 
14. I often feel that others have it in for me. ☐ True    ☐ False ☐ 1        ☐ 2        ☐ 3          
☐ 4 
15. I have had the sense that some person or 
force is around me, even though I could not 
see anyone. 
☐ True    ☐ False ☐ 1        ☐ 2        ☐ 3          
☐ 4 
16. I feel that parts of my body have changed 
in some way, or that parts of my body are 
working differently than before. 
☐ True    ☐ False ☐ 1        ☐ 2        ☐ 3          
☐ 4 
 
 
[34] 
 
If a psychotic disorder is suspected for the first time, rapid assessment by a 
specialist mental health services is indicated [35]. The assessment should include a 
careful evaluation of symptoms, a psychosocial assessment, and a risk assessment 
[35,36]. Conditions that can cause secondary psychosis (e.g., substance use 
disorders) should also be investigated as indicated. If medication is required, then 
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medication choice will be influenced by both comorbid medical conditions such as 
renal or hepatic disease and by anticipated side effects such as dyslipidaemias, 
impaired glucose tolerance, hyperprolactinaemia, and QTc prolongation. For these 
reasons, preliminary investigations often include renal and liver function tests, a 
metabolic profile (height, weight, blood pressure, and lipid and glucose profiles), 
prolactin levels, and an electrocardiogram [36].  
 
PREVALENCE 
The lifetime prevalence of bipolar disorder in the general population is approximately 
0.4% for type I and 0.6% for type II; sub-threshold symptoms are more common, at 
around 1.4% [37].  Lifetime prevalence of schizophrenia and related disorders is 
thought to be around 0.5%, but with regional variations [38]. To date, there are no 
reliable prevalence data on either bipolar or psychotic disorders in elite athletes [39–
41]. However, schizophrenia seems to be under-represented in elite athletes [42]. 
The late teens and early twenties are the peak age of performance in many sports, 
and close to the peak age of onset of conditions such as bipolar and psychotic 
disorders [1]. Thus, it would be expected that elite athletes could present with either 
condition, if only by coincidence. 
 
IMPACT ON PERFORMANCE 
Case reports of high-profile athletes with bipolar disorder indicate that the condition 
is not incompatible with sporting success [43]. In addition, bipolar disorder is 
episodic, with relatively euthymic periods in between symptomatic episodes [3,4]. 
When hypomanic, an athlete’s training might not be unduly compromised, and 
functional impairment is not always found at this stage [2]. However, as symptoms 
increase, concentration, decision-making, and organisation are affected with 
associated functional impairments including difficulty participating in sport, exercise, 
and physical activity [44]. Vigorous exercise may even precipitate or perpetuate 
mania in bipolar disorder [45], such that elite athletes with bipolar disorder may be 
limited in the maximum amount of exercise they can safely undertake without risk of 
mood destabilisation. This situation can be problematic when insight becomes 
impaired, as it often does in emerging mania, and individuals may be reluctant to 
respond to advice to change behaviours and activity patterns because they perceive 
no need to do so. 
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Although bipolar disorder is an episodic illness, individuals can expect to spend 
significant amounts of time in a symptomatic state. In one survey over an average of 
12.8 years, those with bipolar I disorder spent 47.3% of the time experiencing 
symptoms.  Depressive symptoms were the commonest (39% of the time) but were 
often sub-syndromal [4]. A similar survey reported that individuals with bipolar II 
disorder were symptomatic 53.9% of the time, over an average of 13.4 years, with 
depressive symptoms the commonest (50.3% of the time) [3]. 
 
Approximately 40% of people with bipolar disorder have some associated cognitive 
impairment [46]. All cognitive domains are affected (including attention, executive 
function, and memory), even when mood symptoms are relatively absent [47]. The 
severity of impairment seems greatest in those suffering from type I bipolar disorder 
and in those with psychotic symptoms [48], but in general is not as problematic as in 
schizophrenia [49]. There is promise that early initiation of effective treatments may 
prevent or attenuate cognitive deficits [50]. 
 
Symptoms in schizophrenia (and related psychoses) are often grouped into five 
domains, as illustrated in Figure 1.  Although some people with schizophrenia can 
expect a good outcome, a significant number will experience a more chronic and 
pervasive course with a resultant impact on sporting, academic, employment, and 
social function. Symptoms in the cognitive and negative domains are primarily 
associated with functional impairment [51,52]. Longer-term symptoms in the negative 
domain, especially avolition and amotivation (lack of initiative for purposeful tasks), 
may negatively impact significantly on commitment and ability to sustain elite-level 
sports participation. Difficulties with executive function and working memory would 
be expected to impair ability to pursue most activities requiring processing speed 
and complex execution, including elite sports performance. Schizophrenia is thus 
likely to interfere with the demands of elite athletes for both training and competition. 
That this condition appears to be under-represented among elite athletes may relate 
to these issues [42]. 
 
Figure 2. Symptom domains in schizophrenia  
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MANAGEMENT 
Delayed treatment of bipolar disorder [53] and long-standing untreated psychosis 
[54] both correlate with a worse outcome. 
Clinical staging [55] offers a longitudinal perspective of bipolar and psychotic 
disorders, from an at-risk state (i.e., no symptoms), through attenuated or sub-
threshold syndromes, to first and potentially subsequent episodes. In sub-threshold 
stages, psychological interventions and regular monitoring are recommended [56], 
Mood stabilising or antipsychotic medication is typically reserved for the first episode 
of a diagnosed disorder, given the side effect profile of these medications [57]. 
 
Exercise and Psychotherapy interventions 
Although individuals with bipolar and psychotic disorders may have difficulties 
sustaining high-level sport performance, there are potential benefits to continuing 
recreational exercise and sport. Adolescent athletes report multiple mental health 
benefits of sports participation, especially in team sports [58]. Moderate levels of 
physical activity may also benefit symptoms of bipolar and psychotic disorders 
[45,59,60], although there remains a relative lack of research on the relationships 
between high volume and high-intensity athletic training and symptoms of bipolar 
disorder or psychosis. Exercise can help former athletes diagnosed with psychosis to 
establish a new sense of self and purpose in recovery [61]. Maintaining activities 
contributes to the experience of recovery that includes finding meaning in and 
developing a sense of agency, identity, and engagement with life [62]. Many 
individuals experiencing psychotic disorders encounter challenges with relationships 
and broader social inclusion; in such cases, physical activity and sports participation 
can help individuals sustain functioning [63].  
Hippocampal volume is lower than expected in individuals diagnosed with either 
bipolar disorder or schizophrenia [64], but can be increased by exercise in both 
patients and healthy controls, with associated improvements in cognitive function 
[65]. Exercise may also improve neuroplasticity and promote neurogenesis in 
affected individuals; in addition, cardiorespiratory fitness may attenuate the changes 
in brain volume among those with schizophrenia [66]. However, it is unknown if 
improved cognitive function or degree of attenuation can prevent illness progression 
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so that an athlete could sustain an elite level of performance. Exercise may also 
reduce disrupted circadian rhythm and sleep patterns [67] in both schizophrenia [68] 
and bipolar disorder [69]. At present, exercise and physical activity do not feature in 
the practice guidance for either bipolar disorder or schizophrenia in the United 
Kingdom or United States [23,24,35,36].  
 
Psychoeducation is recommended for bipolar disorder [23,24], and has the best 
evidence among all psychotherapy interventions for bipolar disorder within the 
general population [70]. Educational components include information on the nature 
of the illness, factors that can cause destabilisation, use of long-term medications, 
and the appropriate use of short-term medications and other strategies to address 
early signs of relapse. Interpersonal social rhythms therapy also reportedly sustains 
function in bipolar disorder [71,72]. Other psychotherapy interventions that may be 
useful in bipolar disorder include cognitive behavioural therapy, interpersonal 
psychotherapy for bipolar depressive symptoms, and family interventions, although 
much of the evidence is extrapolated from patients with unipolar depression [23,24] 
and none is specific to elite athletes.   
 
Psychotherapy interventions such as cognitive behavioural therapy and family 
interventions are also recommended for psychotic disorders [35,36], but again there 
is no sports-specific evidence on which to base such treatment in athletes.  While 
family psychoeducation has fairly strong evidence for schizophrenia, that this 
intervention often consists of regularly occurring group meetings may be 
incompatible with elite athletes’ travel schedules and desire for confidentiality.    
 
Medication management 
There is limited evidence regarding medication treatment of bipolar disorder and 
psychotic conditions in athletes [39–41]; guidance comes primarily from extrapolation 
from general population recommendations, and from expert opinion regarding athlete 
prescribing. Overall, an approach of ‘carefully considered individual prescribing’ is 
recommended [73]. One important element of this is to consider the potential 
negative impact of medication side effects on athletic performance [73,74]. This is 
accompanied by the need to understand the impact of an athlete’s physiological 
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stressors on both pharmacodynamics (the effect of the drug on the athlete) and 
pharmacokinetics (how the athlete’s body handles the drug) [73,74]. 
 
Guidance for the treatment of bipolar disorder needs to address acute 
mania/hypomania, acute depression, mood episodes with mixed features, and long-
term prophylactic treatment to minimise recurrence [13,23,24].  During acute mania, 
antipsychotics can have a rapid anti-manic effect and may be augmented with short-
term benzodiazepines [13,23,24]. First- (e.g., haloperidol) and second- (e.g., 
aripiprazole, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone) generation 
antipsychotics can be used, with some guidance for the general population preferring 
second-generation drugs [24]. Aripiprazole is recommended as the first choice in the 
general adolescent population because of its more favourable metabolic profile [23], 
which may be a consideration relevant to elite athletes as well. In those with less 
severe mania, monotherapy with valproate or lithium can be considered [24], 
although valproate should typically not be used in women of childbearing age, an 
age group into which most elite women athletes fall. For those who relapse while 
prescribed medication, it is helpful to begin by assessing treatment adherence and 
optimising existing treatments (e.g., by checking lithium or valproate blood levels and 
increasing dosages if necessary) [13,23,24]. When mixed features are present, 
guidance suggests following treatment as for acute mania [13].   
 
In the depressive phase of bipolar disorder, optimising existing treatments is also 
recommended [13,24]. Quetiapine, lurasidone, or olanzapine plus fluoxetine are 
particularly evidence-based choices in the general population [13]. Lamotrigine also 
has efficacy [75], but requires slow titration over weeks. The evidence for lithium is 
more equivocal in acute treatment, but it is recommended if there is previous 
evidence of effectiveness [13], and it is more likely to be efficacious when combined 
with lamotrigine [76]. Antidepressants have generally not been proven effective in 
treating bipolar depression [77].  If an antidepressant is used, some individuals 
appear to respond to selective serotonin reuptake inhibitors (SSRIs), which appear 
to be less likely to cause a switch into mania than serotonin and norepinephrine 
reuptake inhibitors (SNRIs) [78] and tricyclic antidepressants [79] Regardless, 
antidepressants should be used cautiously and typically only in combination with a 
long-term anti-manic treatment, especially for individuals with bipolar I disorder [13].   
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For prophylaxis of future mood episodes in bipolar disorder within the general 
population, lithium is a usual first-line treatment and has efficacy in preventing 
relapse into either mania or depression [13,23,24]. Quetiapine may reduce long-term 
depressive and manic relapses [80]. Lamotrigine is more effective at preventing 
depressive relapses, while valproate and antipsychotics such as aripiprazole, 
lurasidone, olanzapine, and risperidone are more effective for preventing manic 
relapses [13,23]. 
 
Data on medication recommendations specifically for athletes with bipolar disorder 
are largely limited to expert opinion.  Lithium and lamotrigine can be used by 
athletes, and sports psychiatrists have expressed preferences for these two drugs 
[81]. Lithium has a narrow therapeutic window and requires careful monitoring, 
especially in athletes [73]. Data on impact of exercise on lithium levels are 
preliminary and mixed.  Sweat loss may lower lithium levels below therapeutic levels 
[82,83], but there is also concern that dehydration may raise levels towards toxicity 
[74]. Lamotrigine, unlike many other medication options, does not cause weight gain 
and might be chosen for this reason [73,81]. Among the second-generation (atypical) 
antipsychotics, aripiprazole, lurasidone, and ziprasidone may be relatively less likely 
to cause sedation and weight gain, often considered problematic for athletes [73,81]. 
Ziprasidone may cause QTc prolongation [84] and thus may not be a first-line choice 
within this class for elite athletes [81]. Quetiapine can be considered but is sedating 
for many, and aripiprazole may cause akathisia, which could negatively impact motor 
function and elite sporting performance [73].   
 
Within the general population, the mainstay of pharmacological treatment in an 
established and sustained psychotic illness is either first- or second-generation 
antipsychotic medication, with clozapine reserved for treatment-resistant cases 
[35,36,85]. Some guidance suggests choosing a drug based on the side effect 
profile, noting that first- and second-generation drugs are broadly equal in efficacy 
[35,85]. Other guidance recommends using second-generation antipsychotics 
preferentially unless there has been a good previous response to a first-generation 
drug [36].  
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When offering treatment for athletes with psychosis, guidance again comes primarily 
from expert opinion. First-generation (typical) antipsychotics are an infrequent choice 
because of sedation, motor side effects, and cardiac concerns [81] and the 
considerations when choosing a second generation drug are similar to those 
described above in relation to bipolar disorder. 
   
No pharmacological treatments approved for either bipolar or psychotic disorders 
require a Therapeutic Use Exemption (TUE). On occasion, beta-blockers have been 
used to manage tremor as a side effect of lithium therapy or akathisia as a side 
effect of antipsychotics; a TUE would be required for this treatment in certain sports 
and situations [86]. Possible pharmacological treatments for athletes are 
summarised in Table 4. 
 
Table 4. ‘Sports specific’ medication options in bipolar disorder and psychosis 
 
 Bipolar mania Bipolar 
depression 
Bipolar 
prophylaxis 
Psychosis 
‘Expert 
opinion’ 
[73] 
 
Aripiprazole 
(but akathisia) 
Quetiapine (but 
sedating) 
 
Lamotrigine  
Quetiapine (but 
sedating) 
Lithium (both 
poles but careful 
monitoring) 
Lamotrigine 
Aripiprazole (but 
akathisia) 
Quetiapine (but 
sedating) 
Aripiprazole 
(but akathisia) 
Quetiapine 
(but sedating) 
 ‘Expert 
opinion’ 
[74] 
Aripiprazole or 
Lurasidone  
(Both less 
sedating and 
fewer metabolic 
or cardiac 
concerns) 
 
Lamotrigine 
Lurasidone  
(Less sedating 
and fewer 
metabolic or 
cardiac concerns) 
Lamotrigine 
Lithium (with 
careful 
monitoring) 
Aripiprazole  or 
Lurasidone  
(Both less 
sedating and 
fewer metabolic 
or cardiac 
concerns) 
Aripiprazole  or 
Lurasidone  
(Both less 
sedating and 
fewer metabolic 
or cardiac 
concerns) 
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Preference 
of sports 
psychiatrists 
[81] 
Aripiprazole or 
Lurasidone  
 
 
Lamotrigine 
Lurasidone  
 
Lamotrigine 
Lithium 
Aripiprazole 
Lurasidone 
Aripiprazole or 
Lurasidone  
(Both less 
sedating and 
fewer metabolic 
or cardiac 
concerns) 
 
[73,74,81] 
 
SUMMARY 
Bipolar and psychotic disorders can have a significant negative impact on individuals 
in the general population, but the prevalence of these disorders among elite athletes 
is unknown. Cross-sectional studies to identify those with bipolar or psychotic 
disorder diagnoses are needed, as are methodologically more robust studies 
describing relationships between performance-enhancing substances and mental 
health symptoms and disorders. Information on particular symptom manifestations 
within sporting populations and population specific screening tools would be 
especially useful. Although accurate prevalence data on bipolar and psychotic 
disorders in elite athletes are lacking, those who practice in sport require at least a 
basic knowledge of these conditions to ensure early identification and facilitate 
access to treatment, and thus improve outcomes.  
 
Bipolar and psychotic disorders can be chronic and/or relapsing conditions where 
medication is recommended to restore and sustain health. Although psychotherapy 
interventions are usually recommended, these non-pharmacological strategies are 
generally in addition to medications rather than as alternatives. This is unlike 
treatments for anxiety disorders and mild or moderate depression, where 
psychotherapy may be an evidence-based alternative, and in attenuated psychosis 
syndrome, where psychotherapy used without medication may prevent symptom 
progression. The absence of athlete-specific medication trials is therefore of 
particular importance. High-quality data on uses of medication at the extremes of 
human physiology (i.e., during intense exercise) and on the performance impact of 
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commonly prescribed medications for bipolar or psychotic disorders are needed. At 
present, prescribers must rely on expert opinion, using information extrapolated from 
general population studies and taking into account the athlete’s physiology and the 
demands of each sport.  
 
Finally, both physical activity and sports participation can have multiple benefits for 
individuals with bipolar or psychotic disorders. Mental health service providers can 
ally with the world of sport, exercise, and fitness for the benefit of patients and to 
help improve outcomes for conditions that can be chronic and relapsing. This 
includes athletes whose illnesses impair their progress and who could be 
encouraged to maintain activities and, if necessary, given a supported exit strategy 
from elite-level sport to a lower or more recreational level of activity.  
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BULLET POINTS 
What is currently known? 
-Bipolar and psychotic disorder symptoms may be primary, a result of 
substance/medication use, or a result of other medical conditions. 
-Bipolar and psychotic disorders often have a significantly negative impact on 
functioning and quality of life. 
-Individuals with bipolar and psychotic disorders may benefit from early treatment. 
-Bipolar and psychotic disorders are typically chronic in nature and generally require 
long-term medication management alongside psychotherapy interventions. 
 
What are the new findings? 
-A diagnosis of bipolar or psychotic disorders may be more difficult to make in an 
elite athlete because of complicating factors related to the modifying role of exercise 
and potential precipitating impact of substance use. 
-Symptoms of bipolar and psychotic disorders may have a negative impact on sport 
performance and may often be incompatible with elite level sport participation, 
though there may be an important role for continued exercise at lower levels of 
participation even if elite-level competition is not possible. 
-Medications used to treat bipolar and psychotic disorders may have many side-
effects particularly problematic for elite athletes, though there is a need for more 
study of pharmacological options within this population. 
-More research is needed on the incidence and prevalence of bipolar and psychotic 
disorders within elite athletes, particular symptom 
 
  
 
 
25 
REFERENCES 
1  Moesch K, Kenttä G, Kleinert J, et al. FEPSAC position statement: Mental 
health disorders in elite athletes and models of service provision. Psychol 
Sport Exerc 2018;38:61–71. doi:10.1016/J.PSYCHSPORT.2018.05.013 
2  American Psychiatric Association. Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5). 5th ed. Washington, DC: : American Psychiatric Publishing 
2013. https://www.appi.org/Course/Book/Subscription/JournalSubscription/id-
3322/Diagnostic_and_Statistical_Manual_of_Mental_Disorders_%28DSM-
5®%29 (accessed 29 Jun 2018). 
3  Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the 
natural history of the long-term weekly symptomatic status of bipolar II 
disorder. Arch Gen Psychiatry 2003;60:261–
9.http://www.ncbi.nlm.nih.gov/pubmed/12622659 (accessed 4 Aug 2018). 
4  Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the 
weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 
2002;59:530–7.http://www.ncbi.nlm.nih.gov/pubmed/12044195 (accessed 4 
Aug 2018). 
5  Goldberg JF, Perlis RH, Bowden CL, et al. Manic Symptoms During 
Depressive Episodes in 1,380 Patients With Bipolar Disorder: Findings From 
the STEP-BD. 2009. http://edengalaxy.com/images/PDFs/111-bipolar-expert-
specialist-manic-psychotherapist-psychologist.pdf (accessed 9 Jan 2019). 
6  Swann AC, Lafer B, Perugi G, et al. Bipolar Mixed States: An International 
Society for Bipolar Disorders Task Force Report of Symptom Structure, 
Course of Illness, and Diagnosis. Am J Psychiatry 2013;170:31–42. 
doi:10.1176/appi.ajp.2012.12030301 
7  Hantouche EG, Akiskal HS, Lancrenon S, et al. Systematic clinical 
methodology for validating bipolar-II disorder: data in mid-stream from a 
French national multi-site study (EPIDEP). J Affect Disord 1998;50:163–
73.http://www.ncbi.nlm.nih.gov/pubmed/9858076 (accessed 20 Apr 2018). 
8  Tsuang MT, Van Os J, Tandon R, et al. Attenuated psychosis syndrome in 
DSM-5. Schizophr Res 2013;150:31–5. doi:10.1016/j.schres.2013.05.004 
9  Rice SM, McGorry PD, Amminger GP, et al. Current versus recently resolved 
attenuated psychotic symptoms: Same level of risk for transition to psychosis? 
 
 
26 
Schizophr Res 2018;:9–10. doi:10.1016/j.schres.2018.09.023 
10  Kelleher I, Connor D, Clarke MC, et al. Prevalence of psychotic symptoms in 
childhood and adolescence: a systematic review and meta-analysis of 
population-based studies. Psychol Med 2012;42:1857–63. 
doi:10.1017/S0033291711002960 
11  Lin A, Wood SJ, Nelson B, et al. Outcomes of Nontransitioned Cases in a 
Sample at Ultra-High Risk for Psychosis. Am J Psychiatry 2015;172:249–58. 
doi:10.1176/appi.ajp.2014.13030418 
12  Khan H, Sami M, Nilforooshan R. Late onset mania as an organic illness – a 
review of case reports. J Neurol Neurosurg Psychiatry 2016;87:e1. 
doi:10.1136/jnnp-2016-315106.212 
13  Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for 
treating bipolar disorder: Revised third edition recommendations from the 
British Association for Psychopharmacology. J Psychopharmacol 
2016;30:495–553. doi:10.1177/0269881116636545 
14  Silver JM, Kramer R, Greenwald S, et al. The association between head 
injuries and psychiatric disorders: Findings from the New Haven NIMH 
Epidemiologic Catchment Area Study. Brain Inj 2001;15:935–45. 
doi:10.1080/02699050110065295 
15  Creado S, Reardon C. The sports psychiatrist and performance-enhancing 
drugs. Int Rev Psychiatry 2016;28:564–71. 
doi:10.1080/09540261.2016.1190690 
16  Baron DA, Reardon CL, Baron SH. Doping in Sport. In: Baron DA, Reardon 
CL, Baron SH, eds. Clinical Sports Psychiatry: An International Perspective. 
Oxford: : John Wiley & Sons 2013. 21–32. doi:10.1002/9781118404904.ch3 
17  Piacentino D, Kotzalidis G, Casale A, et al. Anabolic-androgenic Steroid use 
and Psychopathology in Athletes. A Systematic Review. Curr Neuropharmacol 
2015;13:101–21. doi:10.2174/1570159X13666141210222725 
18  Markser V, Currie A, McAllister-Williams RH. Mood disorders. In: Currie A, 
Owen B, eds. Sports Psychiatry. Oxford: : Oxford University Press 2016. 31–
51. 
19  Reardon C, Creado S. Drug abuse in athletes. Subst Abuse Rehabil 2014;:95–
105. doi:10.2147/SAR.S53784 
20  Bahrke MS. Psychological and Behavioral Effects of Anabolic -Androgenic 
 
 
27 
Steroids. Int J Sport Exerc Psychol 2005;3:428–45. 
doi:10.1080/1612197X.2005.10807316 
21  Trenton AJ, Currier GW. Behavioural manifestations of anabolic steroid use. 
CNS Drugs 2005;19:571–95.http://www.ncbi.nlm.nih.gov/pubmed/15984895 
(accessed 18 Mar 2018). 
22  Morse ED. Substance Use in Athletes. In: Clinical Sports Psychiatry. Oxford: : 
John Wiley & Sons 2013. 1–12. doi:10.1002/9781118404904.ch1 
23  National Institute for Health and Care Excellence. Bipolar Disorder (update): 
the assessment and management of bipolar disorder in adults, children and 
young people in primary and secondary care. 2014.  
24  Hirschfield RMA, Bowden CL, Gitlin MJ, et al. Treatment of Patients With 
Bipolar Disorder Second Edition. APA Pract Guidel 2010;:1–82. 
doi:10.1176/appi.books.9780890423363.50051 
25  Sylvia LG, Friedman ES, Kocsis JH, et al. Association of exercise with quality 
of life and mood symptoms in a comparative effectiveness study of bipolar 
disorder. J Affect Disord 2013;151:722–7. doi:10.1016/j.jad.2013.07.031 
26  Strohle A, Hofler M, Pfister H, et al. Physical activity and prevalence and 
incidence of mental disorders in adolescents and young adults. Psychol Med 
2007;37:1657–66. doi:10.1017/S003329170700089X 
27  Wright K, Armstrong T, Taylor A, et al. ‘It’s a double edged sword’: A 
qualitative analysis of the experiences of exercise amongst people with Bipolar 
Disorder. J Affect Disord 2012;136:634–42. doi:10.1016/j.jad.2011.10.017 
28  Dudek D, Siwek M, Jaeschke R, et al. A web-based study of bipolarity and 
impulsivity in athletes engaging in extreme and high-risk sports. Acta 
Neuropsychiatr 2016;28:179–83. doi:10.1017/neu.2015.44 
29  Duman CH, Schlesinger L, Russell DS, et al. Voluntary exercise produces 
antidepressant and anxiolytic behavioral effects in mice. Brain Res 
2008;1199:148–58. doi:10.1016/j.brainres.2007.12.047 
30  Thomson D, Turner A, Lauder S, et al. A brief review of exercise, bipolar 
disorder, and mechanistic pathways. Front Psychol 2015;6:1–10. 
doi:10.3389/fpsyg.2015.00147 
31  Depue RA, Slater JF, Wolfstetter-Kausch H, et al. A behavioral paradigm for 
identifying persons at risk for bipolar depressive disorder: a conceptual 
framework and five validation studies. J Abnorm Psychol 1981;90:381–
 
 
28 
437.http://www.ncbi.nlm.nih.gov/pubmed/7298991 (accessed 4 Jan 2019). 
32  Urosević S, Abramson LY, Harmon-Jones E, et al. Dysregulation of the 
behavioral approach system (BAS) in bipolar spectrum disorders: review of 
theory and evidence. Clin Psychol Rev 2008;28:1188–205. 
doi:10.1016/j.cpr.2008.04.004 
33  van Os J, Linscott RJ, Myin-Germeys I, et al. A systematic review and meta-
analysis of the psychosis continuum: evidence for a psychosis proneness–
persistence–impairment model of psychotic disorder. Psychol Med 
2009;39:179. doi:10.1017/S0033291708003814 
34  Ising HK, Veling W, Loewy RL, et al. The validity of the 16-item version of the 
Prodromal Questionnaire (PQ-16) to screen for ultra high risk of developing 
psychosis in the general help-seeking population. Schizophr Bull 
2012;38:1288–96. doi:10.1093/schbul/sbs068 
35  National Institute for Health and Care Excellence. Psychosis and 
schizophrenia in adults : prevention and management. 2014.  
36  Lehman AF, Lieberman JA, Dixon LB, et al. Practice Guideline for the 
Treatment of Patients With Schizophrenia. 2nd ed. Washington DC: 2010. 
doi:http://dx.doi.org/10.1037/0003-066X.57.12.1052 
37  Merikangas KR, Jin R, He J-P, et al. Prevalence and correlates of bipolar 
spectrum disorder in the world mental health survey initiative. Arch Gen 
Psychiatry 2011;68:241–51. doi:10.1001/archgenpsychiatry.2011.12 
38  Goldner EM, Hsu L, Waraich P, et al. Prevalence and Incidence Studies of 
Schizophrenic Disorders: A Systematic Review of the Literature. Can J 
Psychiatry 2002;47:833–43. doi:10.1177/070674370204700904 
39  Rice SM, Purcell R, De Silva S, et al. The Mental Health of Elite Athletes: A 
Narrative Systematic Review. Sport Med 2016;46:1333–53. 
doi:10.1007/s40279-016-0492-2 
40  Reardon CL. Psychiatric Comorbidities in Sports. Neurol Clin 2017;35:537–46. 
doi:10.1016/j.ncl.2017.03.007 
41  Reardon CL, Factor RM. Sport Psychiatry: A systematic review of diagnosis 
and medical treatment of mental illness in athletes. Sport Med 2010;40:961–
80. doi:10.2165/11536580-000000000-00000 
42  Ströhle A. Sports psychiatry: mental health and mental disorders in athletes 
and exercise treatment of mental disorders. Eur Arch Psychiatry Clin Neurosci 
 
 
29 
2018;:1–14. doi:10.1007/s00406-018-0891-5 
43  Favor Hamilton S, Tomlinson S. Fast girl : a life spent running from madness. 
1st ed. Harper Collins 2016.  
44  Rosa AR, Reinares M, Michalak EE, et al. Functional Impairment and Disability 
across Mood States in Bipolar Disorder. Value Heal 2010;13:984–8. 
doi:10.1111/j.1524-4733.2010.00768.x 
45  Melo MCA, Daher EDF, Albuquerque SGC, et al. Exercise in bipolar patients: 
A systematic review. J Affect Disord 2016;198:32–8. 
doi:10.1016/j.jad.2016.03.004 
46  Iverson GL, Brooks BL, Langenecker SA, et al. Identifying a cognitive 
impairment subgroup in adults with mood disorders. J Affect Disord 
2011;132:360–7. doi:10.1016/j.jad.2011.03.001 
47  Robinson LJ, Thompson JM, Gallagher P, et al. A meta-analysis of cognitive 
deficits in euthymic patients with bipolar disorder. J Affect Disord 2006;93:105–
15. doi:10.1016/j.jad.2006.02.016 
48  Bora E. Neurocognitive features in clinical subgroups of bipolar disorder: A 
meta-analysis. J Affect Disord 2018;229:125–34. 
doi:10.1016/j.jad.2017.12.057 
49  Carvalho AF, Bortolato B, Miskowiak K, et al. Cognitive dysfunction in bipolar 
disorder and schizophrenia: a systematic review of meta-analyses. 
Neuropsychiatr Dis Treat 2015;11:3111. doi:10.2147/NDT.S76700 
50  Berk M, Dandash O, Daglas R, et al. Neuroprotection after a first episode of 
mania: a randomized controlled maintenance trial comparing the effects of 
lithium and quetiapine on grey and white matter volume. Transl Psychiatry 
2017;7:e1011. doi:10.1038/tp.2016.281 
51  Green MF. What are the functional consequences of neurocognitive deficits in 
schizophrenia? Am J Psychiatry 1996;153:321–30. doi:10.1176/ajp.153.3.321 
52  Rabinowitz J, Levine SZ, Garibaldi G, et al. Negative symptoms have greater 
impact on functioning than positive symptoms in schizophrenia: Analysis of 
CATIE data. Schizophr Res 2012;137:147–50. 
doi:10.1016/j.schres.2012.01.015 
53  Joyce K, Thompson A, Marwaha S. Is treatment for bipolar disorder more 
effective earlier in illness course? A comprehensive literature review. Int J 
Bipolar Disord 2016;4:1–9. doi:10.1186/s40345-016-0060-6 
 
 
30 
54  Penttilä M, Jaä̈skel̈ainen E, Hirvonen N, et al. Duration of untreated psychosis 
as predictor of long-term outcome in schizophrenia: Systematic review and 
meta-analysis. Br J Psychiatry 2014;205:88–94. 
doi:10.1192/bjp.bp.113.127753 
55  Berk M, Post R, Ratheesh A, et al. Staging in bipolar disorder: from theoretical 
framework to clinical utility. World Psychiatry 2017;16:236–44. 
doi:10.1002/wps.20441 
56  Fusar-Poli P, Borgwardt S, Bechdolf A, et al. The Psychosis High-Risk State; A 
Comprehensive State-of-the-Art Review Paolo. JAMA Psychiatry 
2013;70:107–20. doi:10.1001/jamapsychiatry.2013.269 
57  Liu C-C, Demjaha A. Antipsychotic Interventions in Prodromal Psychosis. CNS 
Drugs 2013;27:197–205. doi:10.1007/s40263-013-0046-1 
58  Swann C, Telenta J, Draper G, et al. Youth sport as a context for supporting 
mental health: Adolescent male perspectives. Psychol Sport Exerc 
2018;35:55–64. doi:10.1016/j.psychsport.2017.11.008 
59  Firth J, Cotter J, Elliott R, et al. A systematic review and meta-analysis of 
exercise interventions in schizophrenia patients. Psychol Med 2015;45:1343–
61. doi:10.1017/S0033291714003110 
60  Dauwan M, Begemann MJH, Heringa SM, et al. Exercise Improves Clinical 
Symptoms, Quality of Life, Global Functioning, and Depression in 
Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull 
2016;42:588–99. doi:10.1093/schbul/sbv164 
61  Carless D. Narrative, Identity, and Recovery from Serious Mental Illness: A 
Life History of a Runner. Qual Res Psychol 2008;5:233–48. 
doi:10.1080/14780880701826101 
62  Andresen R, Oades L, Caputi P. The Experience of Recovery from 
Schizophrenia: Towards an Empirically Validated Stage Model. Aust New Zeal 
J Psychiatry 2003;37:586–94. doi:10.1046/j.1440-1614.2003.01234.x 
63  Currie A, Malik R. Exercise participation and mental health. In: Currie A, Owen 
B, eds. Sports Psychiatry. Oxford: : Oxford University Press 2016. 107–16. 
64  Haukvik UK, Tamnes CK, Söderman E, et al. Neuroimaging hippocampal 
subfields in schizophrenia and bipolar disorder: A systematic review and meta-
analysis. J Psychiatr Res 2018;104:217–26. 
doi:10.1016/j.jpsychires.2018.08.012 
 
 
31 
65  Pajonk F-G, Wobrock T, Gruber O, et al. Hippocampal Plasticity in Response 
to Exercise in Schizophrenia. Arch Gen Psychiatry 2010;67:133–
43.https://pdfs.semanticscholar.org/0c49/2b8dcac2f03baff652a2df1c7c1efb50
06a9.pdf (accessed 28 Mar 2018). 
66  Scheewe TW, van Haren NE, Sarkisyan G, et al. Exercise therapy, 
cardiorespiratory fitness and their effect on brain volumes: A randomised 
controlled trial in patients with schizophrenia and healthy controls. Eur 
Neuropsychopharmacol 2013;23:675–85. 
doi:10.1016/j.euroneuro.2012.08.008 
67  Brand S, Gerber M, Beck J, et al. High Exercise Levels Are Related to 
Favorable Sleep Patterns and Psychological Functioning in Adolescents: A 
Comparison of Athletes and Controls. J Adolesc Heal 2010;46:133–41. 
doi:10.1016/j.jadohealth.2009.06.018 
68  Wulff K, Dijk D-J, Middleton B, et al. Sleep and circadian rhythm disruption in 
schizophrenia. Br J Psychiatry 2012;200:308–16. 
doi:10.1192/bjp.bp.111.096321 
69  Bradley AJ, Webb-Mitchell R, Hazu A, et al. Sleep and circadian rhythm 
disturbance in bipolar disorder. Psychol Med 2017;47:1678–89. 
doi:10.1017/S0033291717000186 
70  Colom F, Vieta E, Reinares M, et al. Psychoeducation efficacy in bipolar 
disorders: beyond compliance enhancement. J Clin Psychiatry 2003;64:1101–
5.http://www.ncbi.nlm.nih.gov/pubmed/14628987 (accessed 31 Jan 2019). 
71  Frank E, Swartz HA, Kupfer DJ. Interpersonal and social rhythm therapy: 
managing the chaos of bipolar disorder. Biol Psychiatry 2000;48:593–
604.http://www.ncbi.nlm.nih.gov/pubmed/11018230 (accessed 10 Oct 2018). 
72  Frank E, Soreca I, Schwartz H, et al. The Role of Interpersonal and Social 
Rhythm Therapy in Improving Occupational Functioning in Patients With 
Bipolar I Disorder. Am J Psychiatry 2008;165:1559–65. 
doi:1doi:10.1176/appi.ajp.2008.07121953 
73  Johnston A, McAllister-Williams RH. Psychotropic Drug Prescribing. In: Currie 
A, Owen B, eds. Sports Psychiatry. Oxford: : Oxford University Press 2016. 
133–43. 
74  Reardon CL. The sports psychiatrist and psychiatric medication. Int Rev 
Psychiatry 2016;28:606–13. doi:10.1080/09540261.2016.1190691 
 
 
32 
75  Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar 
depression: independent meta-analysis and meta-regression of individual 
patient data from five randomised trials. Br J Psychiatry 2009;194:4–9. 
doi:10.1192/bjp.bp.107.048504 
76  van der Loos MLM, Mulder PGH, Hartong EGTM, et al. Efficacy and safety of 
lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, 
double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:223–
31.http://www.ncbi.nlm.nih.gov/pubmed/19200421 (accessed 24 Oct 2018). 
77  Sidor MM, MacQueen GM. Antidepressants for the Acute Treatment of Bipolar 
Depression. J Clin Psychiatry 2011;72:156–67. doi:10.4088/JCP.09r05385gre 
78  Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: 
comparison of adjunctive venlafaxine, bupropion and sertraline. Br J 
Psychiatry 2006;189:124–31. doi:10.1192/bjp.bp.105.013045 
79  Peet M. Induction of mania with selective serotonin re-uptake inhibitors and 
tricyclic antidepressants. Br J Psychiatry J Ment Sci 1994;164:549–
50.http://www.ncbi.nlm.nih.gov/pubmed/8038948 (accessed 24 Oct 2018). 
80  Weisler RH, Nolen WA, Neijber A, et al. Continuation of Quetiapine Versus 
Switching to Placebo or Lithium for Maintenance Treatment of Bipolar I 
Disorder. J Clin Psychiatry 2011;72:1452–64. doi:10.4088/JCP.11m06878 
81  Reardon CL, Creado S. Psychiatric medication preferences of sports 
psychiatrists. Physician Sport Med 2016;44:397–402. 
doi:10.1080/00913847.2016.1216719 
82  Jefferson JW, Greist JH, Clagnaz PJ, et al. Effect of strenuous exercise on 
serum lithium level in man. Am J Psychiatry 1982;139:1593–5. 
doi:10.1176/ajp.139.12.1593 
83  Miller EB, Pain RW, Skripal PJ. Sweat lithium in manic-depression. Br J 
Psychiatry 1978;133:477–8.http://www.ncbi.nlm.nih.gov/pubmed/728699 
(accessed 11 Jul 2018). 
84  Beach SR, Celano CM, Noseworthy PA, et al. QTc Prolongation, Torsades de 
Pointes, and Psychotropic Medications. Psychosomatics 2013;54:1–13. 
doi:10.1016/j.psym.2012.11.001 
85  Barnes T, Schizophrenia Consensus Group of British Association of 
Psychopharmacology. Evidence-based guidelines for the pharmacological 
treatment of schizophrenia: recommendations from the British Association for 
 
 
33 
Psychopharmacology. J Pharmacol 2011;25:567–620. 
doi:10.1177/0269881110391123 
86  Kaufman KR, Campeas M, Coluccio M, et al. Bipolar disorders and comorbid 
conditions – Ethical considerations in sports. Apunt Med l’Esport 2018;53:55–
61. doi:10.1016/j.apunts.2017.10.001 
 
